Abstract
Chemoimmunotherapy with adjuvant CL/MAb 231 offers an alternative treatment approach for canine lymphoma. Results of treatment and prognostic factors are discussed and compared with previously published chemotherapy results.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antibodies, Monoclonal / therapeutic use*
-
Dog Diseases / therapy*
-
Dogs
-
Drug Therapy / standards
-
Drug Therapy / veterinary
-
Immunotherapy / standards
-
Immunotherapy / veterinary*
-
Lymphoma / therapy
-
Lymphoma / veterinary*